Sierra Oncology, Inc.: management transactions · United States · SEC (Form 4)

About Sierra Oncology, Inc.

Sierra Oncology, Inc. was a U.S.-listed biopharmaceutical company that traded on NASDAQ under the ticker SRRA before being acquired by GSK, with the transaction completed on July 1, 2022. The company was incorporated in the United States and was headquartered in San Mateo, California. From an equity-analysis perspective, Sierra Oncology fit the profile of a specialty biotech: a focused development-stage platform built around a narrow set of high-value clinical assets rather than a broad commercial portfolio. ([gsk.com](https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-sierra-oncology/?utm_source=openai)) Its core business was the development of targeted therapies for rare cancers, with particular emphasis on hematology-oncology. The lead asset was momelotinib, a late-stage investigational medicine designed for patients with myelofibrosis, especially those with anemia. That therapeutic focus mattered because myelofibrosis is a rare blood cancer with substantial symptom burden and limited treatment options, making differentiated mechanisms of action commercially and clinically important. Sierra’s value proposition was therefore centered on clinical execution, regulatory progress, and eventual label differentiation rather than on recurring product sales or broad operating scale. ([gsk.com](https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-sierra-oncology/?utm_source=openai)) In terms of history, Sierra Oncology developed as a research-driven biotech with activities concentrated in the United States and, through regulatory filing pathways, Europe. The company’s 2022 regulatory work around momelotinib became the key catalyst that attracted strategic interest from larger pharmaceutical players. GSK announced an agreement to acquire Sierra Oncology for about $1.9 billion, and later confirmed completion of the acquisition. That deal effectively monetized the company’s main clinical asset and ended Sierra Oncology’s life as an independent public issuer. ([gsk.com](https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-to-acquire-late-stage-biopharmaceutical-company-sierra-oncology-for-19bn/?utm_source=openai)) For investors in France, Belgium, and Switzerland, the case is important mainly as a historical U.S. biotech compendium rather than a current operating equity story. The company was listed on NASDAQ in the United States, and its market relevance came from one principal program, momelotinib, plus the strategic optionality embedded in the anemia segment of myelofibrosis care. Sierra Oncology did not have the diversified product mix of a commercial pharma group; instead, it was a pipeline-centric specialist whose competitive standing depended on clinical differentiation, regulatory milestones, and partner or acquirer interest. Following the GSK acquisition, subsequent market relevance is primarily confined to legacy SEC records, including insider-transaction filings such as Form 4, rather than ongoing public-market operations. ([gsk.com](https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-to-acquire-late-stage-biopharmaceutical-company-sierra-oncology-for-19bn/?utm_source=openai))